Related Experiment Videos
First experience with a new nonthoracotomy defibrillation lead system
H J Trappe1, P Pfitzner, P Wenzlaff
1Department of Cardiology, University Hospital, Ruhr-University Bochurn, Herne, Germany.
American Heart Journal
|September 1, 1996
Summary
The new TVL lead system for defibrillation is safe and effective for treating ventricular tachyarrhythmias. This system successfully terminated all arrhythmic episodes with a high success and low complication rate.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Life-threatening ventricular tachyarrhythmias require effective defibrillation strategies.
- Nonthoracotomy lead systems offer a less invasive approach to defibrillation therapy.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of a novel nonthoracotomy defibrillation lead system (TVL lead system).
- To assess the performance of the TVL lead system in patients with ventricular tachycardia or fibrillation.
Main Methods:
- Implantation of the TVL lead system and Cadence pulse generator was attempted in 27 patients.
- A subcutaneous patch lead was added as needed for adequate defibrillation energy.
- Patients were monitored for an average of 6 months, with defibrillation thresholds assessed at implant, predischarge, and 4-month follow-up.
Main Results:
- Successful implantation was achieved in 96% of patients, with 88% in a lead-alone configuration.
- The mean defibrillation threshold remained stable from implant to 4-month follow-up.
- No deaths, infections, or lead-related complications were reported. All 545 spontaneous arrhythmic episodes in 8 patients were successfully terminated.
Conclusions:
- The TVL lead system, combined with the Cadence tiered-therapy defibrillator, demonstrates a high success rate in treating ventricular tachyarrhythmias.
- The system exhibits a low complication rate, making it a viable option for patients with life-threatening arrhythmias.